Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald E Mager

Showing results (71-80 of 163) with videos related to

Pageof 17
Sort By:
Pharmaceutical Research|March 27, 2007
Population pharmacokinetic/pharmacodynamic modeling of systemic corticosteroid inhibition of whole blood lymphocytes: modeling interoccasion pharmacodynamic variabilityYing Hong, Donald E Mager, Robert A Blum, et al.
Biochemical Pharmacology|May 12, 2009
Mechanisms of interferon-beta effects on bone homeostasisAnson K Abraham, Murali Ramanathan, Bianca Weinstock-Guttman, et al.
Pharmaceutical Research|March 17, 2010
Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferonsLeonid Kagan, Anson K Abraham, John M Harrold, et al.
The AAPS Journal|October 8, 2021
Cluster Gauss-Newton and CellNOpt Parameter Estimation in a Small Protein Signaling Network of Vorinostat and Bortezomib PharmacodynamicsJin Niu, Van Anh Nguyen, Mohammad Ghasemi, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 12, 2015
Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma CellsVaishali L Chudasama, Meric A Ovacik, Darrell R Abernethy, et al.
Pharmaceutical Research|July 19, 2012
Pharmacokinetics and pharmacodynamics of anti-BR3 monoclonal antibody in miceAnshu Marathe, Suhasini Iyer, Zhihua Julia Qiu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 9, 2013
Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 statusXi-Ling Jiang, Hong-Wu Shen, Donald E Mager, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 24, 2007
HPLC-atmospheric pressure chemical ionization mass spectrometric method for enantioselective determination of R,S-propranolol and R,S-hyoscyamine in human plasmaDanuta Siluk, Donald E Mager, Naomi Gronich, et al.
BMC Cancer|October 24, 2020
Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cellsJin Niu, Xue Wang, Jun Qu, et al.
Pharmaceutical Research|September 3, 2011
Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in ratsLeonid Kagan, Michael R Turner, Sathy V Balu-Iyer, et al.
Pageof 17

Showing results (71-80 of 163) with videos related to

Sort By:
Pageof 17
Pharmaceutical Research|March 27, 2007
Population pharmacokinetic/pharmacodynamic modeling of systemic corticosteroid inhibition of whole blood lymphocytes: modeling interoccasion pharmacodynamic variabilityYing Hong, Donald E Mager, Robert A Blum, et al.
Biochemical Pharmacology|May 12, 2009
Mechanisms of interferon-beta effects on bone homeostasisAnson K Abraham, Murali Ramanathan, Bianca Weinstock-Guttman, et al.
Pharmaceutical Research|March 17, 2010
Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferonsLeonid Kagan, Anson K Abraham, John M Harrold, et al.
The AAPS Journal|October 8, 2021
Cluster Gauss-Newton and CellNOpt Parameter Estimation in a Small Protein Signaling Network of Vorinostat and Bortezomib PharmacodynamicsJin Niu, Van Anh Nguyen, Mohammad Ghasemi, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 12, 2015
Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma CellsVaishali L Chudasama, Meric A Ovacik, Darrell R Abernethy, et al.
Pharmaceutical Research|July 19, 2012
Pharmacokinetics and pharmacodynamics of anti-BR3 monoclonal antibody in miceAnshu Marathe, Suhasini Iyer, Zhihua Julia Qiu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 9, 2013
Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 statusXi-Ling Jiang, Hong-Wu Shen, Donald E Mager, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 24, 2007
HPLC-atmospheric pressure chemical ionization mass spectrometric method for enantioselective determination of R,S-propranolol and R,S-hyoscyamine in human plasmaDanuta Siluk, Donald E Mager, Naomi Gronich, et al.
BMC Cancer|October 24, 2020
Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cellsJin Niu, Xue Wang, Jun Qu, et al.
Pharmaceutical Research|September 3, 2011
Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in ratsLeonid Kagan, Michael R Turner, Sathy V Balu-Iyer, et al.
Pageof 17